会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明授权
    • Powdery composition for nasal administration
    • 用于鼻腔给药的粉状组合物
    • US08206748B2
    • 2012-06-26
    • US12610901
    • 2009-11-02
    • Masahiko DohiYoshihisa NishibeYuji MakinoTakao Fujii
    • Masahiko DohiYoshihisa NishibeYuji MakinoTakao Fujii
    • A61K9/14A61K9/50
    • A61K9/0043
    • A powdery composition for nasal administration, where (1) the composition contains (i) a drug, (ii) a water-absorbing and gel-forming base material such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose and (iii) a water-absorbing and water-insoluble base material such as crystalline cellulose or α-cellulose, (2) wherein the amount of the water-absorbing and gel-forming base material is about 5-40 wt % based on the total of the water-absorbing and gel-forming base material and the water-absorbing and water-insoluble base material, and (3) wherein the drug is unevenly dispersed more on/in the water-absorbing and water-insoluble base material than on/in the water-absorbing and gel-forming base material.
    • 一种用于鼻腔给药的粉末组合物,其中(1)组合物包含(i)药物,(ii)吸水和凝胶形成基材如羟丙基纤维素或羟丙基甲基纤维素和(iii)吸水和水 - 不溶性基材如结晶纤维素或α-纤维素,(2)其中吸水和凝胶形成基材的量相对于吸水和凝胶形成的总量为约5-40重量% 基材和吸水性和水不溶性基材,和(3)其中药物在吸水性和水不溶性基材中/吸水凝胶形成中的/不均匀分散 基材。
    • 19. 发明授权
    • 1.alpha.,24-(OH).sub.2 -cholecalciferol emulsion composition and method
for treating psoriasis
    • 1α,24-(OH)2 - 胆钙化醇乳剂组合物和治疗牛皮癣的方法
    • US5612327A
    • 1997-03-18
    • US428106
    • 1995-04-28
    • Yuji MakinoHideo MatugiYoshiki Suzuki
    • Yuji MakinoHideo MatugiYoshiki Suzuki
    • A61K9/00A61K31/59A61K47/00A61K47/06A61K47/10A61K47/14A61K47/44
    • A61K9/0014A61K31/59A61K47/06A61K47/10A61K47/14A61K47/44
    • A 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition comprising(a) a therapeutically effective amount of 1.alpha.,24-(OH).sub.2 --V.D.sub.3,(b) an oil phase component including(i) a solid oil component composed of 5 to 20 parts by weight of white petrolatum and 5 to 15 parts by weight of higher alcohols and(ii) a liquid oil component comprising of 3 to 10 parts by weight of squalane,(c) an aqueous phase component, and(d) 2.5 to 7.5 parts by weight at least two surfactants, wherein the 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition has a weight ratio of the solid oil component to the liquid oil component (i.e., solid oil component/liquid oil component) of at least approximately 2, the higher alcohols are composed of stearyl alcohol and cetyl alcohol, the weight ratio of the stearyl alcohol to the higher alcohols (i.e., stearyl alcohol/higher alcohols) is approximately 0.65 to approximately 0.9, at least 50% by weight of the surfactants is at least one surfactant having an HLB value of approximately 5 or less, and the HLB value of the surfactants as a whole is approximately 8 to approximately 18.
    • PCT No.PCT / JP94 / 01443 Sec。 371日期:1995年4月28日 102(e)日期1995年4月28日PCT 1994年9月1日PCT公布。 公开号WO95 / 06482 日期:1995年3月9日A 1α,24-(OH)2-V.D3乳膏组合物,其包含(a)治疗有效量的1α,24-(OH)2-V.D3,(b)油相 组分包括(i)由5至20重量份的白凡士林和5至15重量份的高级醇组成的固体油组分和(ii)包含3至10重量份的角鲨烷的液体油组分( c)水相组分,和(d)2.5至7.5重量份的至少两种表面活性剂,其中所述1α,24-(OH)2-V.D3乳膏组合物具有固体油组分与 液体油组分(即固体油组分/液体油组分)至少约为2,高级醇由硬脂醇和鲸蜡醇组成,硬脂醇与高级醇的重量比(即硬脂醇/更高 醇)为约0.65至约0.9,至少50重量%的表面活性剂是至少一种HLB值为约 实际为5以下,表面活性剂整体的HLB值约为8〜18。